CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation

Immunobiology

Volumn 214, Issue 2, 2009, Pages 153-161

  Senthilkumar, Ramamoorthy ^a   Lee, Hyeon Woo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Apoptosis; CD137L; Osteoclastogenesis; RANKL; Reverse signals; T cell proliferation; TNF

Indexed keywords

CD137 LIGAND; CD3 ANTIBODY; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; FLOW CYTOMETRY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

4-1BB LIGAND; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; OSTEOCLASTS; RANK LIGAND;

EID: 58349112745     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2008.05.001     Document Type: Article

References (33)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Maraskosky E., Billingsky W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., and Calibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
2. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
3. Brunetti G., Colucci S., Pignataro P., Coricciati M., Mori G., Girulli N., Zallone A., Grassi F.R., and Grano M. T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J. Periodontol. 76 10 (2005) 1675-1680
4. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol. 192 (2000) 4-13
5. Eissner G., Kolch W., and Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev. 15 (2004) 353-366
6. Erciyas K., Orbak R., Kavrut F., Demir T., and Kaya H. The changes in T lymphocyte subsets following periodontal treatment in patients with chronic periodontitis. J. Periodontal Res. 41 3 (2006) 165-170
7. Grcevic E., Lukic I.K., Kovacic N., Ivcevic S., Katavic V., and Marusic A. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-κB and c-Fos. Clin. Exp. Immunol. 146 (2006) 146-158
8. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15 (2000) 2-12
9. Kawai T., Matsuyama T., Hosokawa Y., Makihira S., Goncalves R.B., Valverde P., Dibart S., Li Y.P., Miranda L.A., Emst C.W.O., Izumi Y., and Taubman M.A. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 9 (2006) 87-98
10. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
11. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C.R., Lacey D.L., Mak T.W., Boyle W.J., and Penninger J.M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397 (1999) 315-323
12. Kong Y.Y., Boyle W.J., and Penninger J.M. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol. Cell Biol. 77 (1999) 188-193
13. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliot R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
14. Lee H.W., Park S.J., Choi B.K., Kim H.H., Nam K.O., and Kwon B.S. 4-1BB promotes the survival or CD8+ T lymphocytes by increasing expression of Bcl-xl and Bfl-11. J. Immunol. 169 (2002) 4882-4888
15. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Sailly S., Van G., Kaufman S., Juan S.C., Sun Y., Tarpley J., Martin L., Chrisensen K., McCabe J., Kostenuik P., Hsu H., Fletcher F., Dunstan C., Lacey D., and Boyle W.J. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97 (2000) 1566-1571
16. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., Tomonori M., and Higashio K. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253 (1998) 395-400
17. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
18. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 27 (1999) 1229-1241
19. Saito K., Ohara N., Hotokezaka H., Fukumoto S., Yuasa K., Naito M., Fujiwara T., and Nakayama K. Infection-induced upregulation of the costimulatory molecule CD137 in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis. J. Biol. Chem. 279 (2004) 13555-13563
20. Shin H.H., Lee E.A., Kim S.J., Kwon B.S., and Choi H.S. A signal through 4-1BB ligand inhibits receptor for activation of nuclear factor κB ligand (RANKL)-induced osteoclastogenesis by increasing interferon (IFN) β production. FEBS Lett. 580 (2006) 1601-1606
21. Simonet W.S., Lacey D.L., Dunstan C.R., Kelly M., Chang M.S., Luthy R., Nguyen H.Q., Shimamoto G., Derose M., Elliot R., Colomero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
22. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
23. Sun Y., Blink S.E., Liu W., Lee Y., Chen B., Solway J., Weinstock J., Chen L., and Fu Y.X. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J. Immunol. 177 2 (2006) 814-821
24. Takahashi N., Yamana H., Yoshiki S., Roodman G.D., Mundy G.R., Jones S.J., Boyde A., and Suda T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122 (1988) 1373-1382
25. Takahashi N., Udagawa N., and Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256 (1999) 449-455
26. Teitlelbaum S.L. Bone resorption by osteoclasts. Science 289 (2000) 1504-1508
27. Theill L.E., Boyle W.J., and Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20 (2002) 795-823
28. Udagawa N., Takahashi N., Yasuda H., Mizuno A., Ttoh K., Ueno Y., Shinki T., Gillespie M.T., Martin J., Higashio K., and Suda T. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141 (2000) 3478-3484
29. Vinay D.S., and Kwon B.S. Role of 4-1BB in immune responses. Semin. Immunol. 10 (1998) 481-489
30. Vinay D.S., and Kwon B.S. Genes, Transcription and Protein of CD137 Receptor and Ligand; CD137 Pathway: Immunology and Diseases. In: Lieping C. (Ed) (2006), Springer, New York
31. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett Jr. F.S., Frankel W.N., Lee S.Y., and Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
32. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S.I., Tomoyasu A., Yano K., Goto K., Goto M., Murakami A., Tsuda E., Moringa T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
33. Zauli G., Rimondi E., Nicolin V., Melloni E., Celeghini C., and Secchiero P. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104 (2004) 2044-2050